Novartis (Mexico) Insiders

NVSN Stock  MXN 2,004  134.33  6.28%   
Novartis employs about 102 K people. The company is managed by 34 executives with a total tenure of roughly 254 years, averaging almost 7.0 years of service per executive, having 3000.0 employees per reported executive. Break down of Novartis' management performance can provide insight into the company performance.
Richard Saynor  CEO
Chief Executive Officer of Sandoz, Member of the Executive Committee
Joerg Reinhardt  Chairman
Independent Non-Executive Chairman of the Board
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Novartis Management Team Effectiveness

The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.

Novartis Workforce Comparison

Novartis AG is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is now estimated at about 102,122. Novartis totals roughly 102,000 in number of employees claiming about 100% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.25 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.25.

Novartis AG Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis AG Price Series Summation is a cross summation of Novartis price series and its benchmark/peer.

Novartis Notable Stakeholders

A Novartis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novartis often face trade-offs trying to please all of them. Novartis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novartis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard SaynorChief Executive Officer of Sandoz, Member of the Executive CommitteeProfile
Joerg ReinhardtIndependent Non-Executive Chairman of the BoardProfile
Daniel VasellaHonorary Chairman of the BoardProfile
Enrico VanniLead Independent Non-Executive Vice Chairman of the BoardProfile
Alex KrauerHonorary Chairman of the BoardProfile
Susanne SchaffertPresident of Novartis Oncology, Member of the Executive CommitteeProfile
James BradnerPresident of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive CommitteeProfile
Harry KirschChief Financial Officer, Member of the Executive CommitteeProfile
Ton BuechnerNon-Executive Independent DirectorProfile
Frans HoutenNon-Executive Independent DirectorProfile
Nancy AndrewsNon-Executive Independent DirectorProfile
Elizabeth DohertyNon-Executive Independent DirectorProfile
Andreas PlantaNon-Executive Independent DirectorProfile
Ann FudgeNon-Executive Independent DirectorProfile
Srikant DatarNon-Executive Independent DirectorProfile
Simon MoroneyNon-Executive Independent DirectorProfile
Bridgette HellerNon-Executive Independent DirectorProfile
Steffen LangGlobal Head of Novartis Technical Operations, Member of the Executive CommitteeProfile
Paul PenepentHead AccountingProfile
Robert PharmDChief OfficerProfile
Karen HaleChief OfficerProfile
Charles SawyersNon-Executive Independent Member of the BoardProfile
Steven BaertChief People & Organization Officer, Member of the Executive CommitteeProfile
John TsaiHead of Global Drug Development and Chief Medical Officer, Member of the Executive CommitteeProfile
Bertrand BodsonChief Digital Officer, Member of the Executive CommitteeProfile
Robert WeltevredenHead of Novartis Business Services (NBS), Member of the Executive CommitteeProfile
Vasant NarasimhanGlobal Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive CommitteeProfile
Patrice BulaNon-Executive Independent DirectorProfile
Charlotte PamerWieserCorporate SecretaryProfile
Shannon KlingerChief Risk and Compliance Officer, Group General CounselProfile
William WintersNon-Executive Independent Member of the BoardProfile
MarieFrance TschudinPresident of Novartis Pharmaceuticals, Member of the Executive CommitteeProfile
Samir MDGlobal RelationsProfile
Klaus MoosmayerChief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeProfile

About Novartis Management Performance

The success or failure of an entity such as Novartis AG often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 105794 people.
Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.

Novartis Workforce Analysis

Traditionally, organizations such as Novartis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novartis within its industry.

Novartis Manpower Efficiency

Return on Novartis Manpower

Revenue Per Employee508.1K
Revenue Per Executive1.5B
Net Income Per Employee68.2K
Net Income Per Executive204.6M

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.